posted
I'm still in thanks to free-ride rules, unfortunately. Any idea if this can rebound? Anyone hear of news coming out, etc? Obviously, in your opinion.
IP: Logged |
posted
I feel like this stock got the exposure it needed, and with everyone watching it now, it'll only take one good news story to shoot it up to 1.5 or 2 cents/share again (imo). Any opinions? Would anyone take the loss (of profit, not principal) and dump it, like tomorrow? I have 200k shares at, an average of, .0069/share. In your opinions, of course.
IP: Logged |
Ingen Takes Next Step With ISO 13485 Certification for China, Japan, Canada and Europe 11 minutes ago (6/10/09 3:26pm Eastern) - Globenewswire
Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company has commenced ISO 13485 staff training this week with the Emergo Group.
The company has signed contracts with the Austin-Texas based Emergo Group to prepare, train and coordinate all International Standard Organization (ISO) 13485 certifications to market and sell Oxyview in China, Japan, Canada and the European Community. In addition to the ISO certification requirement, the contracts also include the CE Mark required to sell Oxyview in Europe.
The training and document specialist with the Emergo Group, Cheryl Fisher, has been training the Ingen management and staff on ISO certification and document requirement procedures. The ISO certification process will take approximately 3-6 months. ISO is a network of the national standards institutes of 161 countries, one member per country, with a Central Secretariat in Geneva, Switzerland, that coordinates the system. ISO is a non-governmental organization that forms a bridge between the public and private sectors. On the one hand, many of its member institutes are part of the governmental structure of their countries, or are mandated by their government. On the other hand, other members have their roots uniquely in the private sector, having been set up by national partnerships of industry associations. Therefore, ISO enables a consensus to be reached on solutions that meet both the requirements of business and the broader needs of society.
"Ingen has invested tens of thousands of dollars with the Emergo Group to insure ISO 13485 certification in countries that have a strong interest and large revenue potential for our Oxyview product, inclusive of our new Oxyview-Cannula product being introduced in the next week," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
IP: Logged |
posted
IGNT gained back some of its losses before close. My opinion is obviously bias (since I own shares of it), but radar it tomorrow in case it moves due to news. They seem to be putting out news stories at a rapid pace recently. Obviously research it yourself since my opinion could be biased.
IP: Logged |
posted
NEWS!! - This is gonna fly today (imo, but it could be biased)
Ingen Gets Good Feedback From COPD Advertisement 12 minutes ago - Investrend (6/11/09 9:00am Eastern)
June 11, 2009 (FinancialWire) -- Ingen Technologies, Inc. (OTC: IGNT) has received an increase in Oxyview orders and telephone orders from COPD patients and new distributor inquiries from the advertisement in the COPD Digest. In March-2009 Ingen signed an insertion order with COPD Digest to run a national advertisement for the new Oxyview. COPD Digest is published by the COPD Foundation, with the support of -- and contributions from -- organizations representing the entire COPD community. Chronic Obstructive Pulmonary Disease affects over 600 million people worldwide. Oxyview provides these patients with the ability to assure oxygen flow and equipment function. "Since the ad was issued last week with over 160,000 circulations, there has been an increase with on-line orders through our website and PayPal, as well as telephone orders. The patients and new potential distributors are very pleased with the new Oxyview product," stated Chris Wirth, Chief Operations officer. Oxyview is a proprietary medical device with U.S.-issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease in the United States, according to the World Health Organization. FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries*financialwire.net. Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).
IP: Logged |
posted
More news, but is it good or bad? I haven't been in the investment world long enough to know if an Acquisition will raise or lower the PPS. Any opinions?
quote:Originally posted by Proto: More news, but is it good or bad? I haven't been in the investment world long enough to know if an Acquisition will raise or lower the PPS. Any opinions?
Well, at this price level, it would probably be a good thing. Doesn't mention if they have gotten any buy-out offers but since they reduced their debt, it could make them more attractive .... imho
-------------------- " Cash is King "
IP: Logged |
Ingen Increases Oxyview Inventory to 162,000 Units for Projected Sales Demands Thursday 06/18/2009 4:15 PM ET - Globenewswire
IGNT 0.0101 3.06%
As of 9:30 AM ET 6/19/09 Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company increased the first shipment of Oxyview-Nasal Cannula orders from 10,000 to 62,000 units, and increased production inventory for June to 100,000 units for a revenue value of $2.8 million. The company notified Legend Medical Devices on Wednesday of this week that the first orders will be increased from 10,000 to 62,000 units for the new Oxyview-Nasal Cannula shipment. Bill Liang, President of Legend Medical Devices has agreed to prepare a revised delivery schedule. The company has received partial shipment and will start advertising the new Oxyview-Nasal Cannula next week. The company website will be updated and this new product will be available next week. In addition, the company has notified their Corona-California based production facility, Accent Plastics Inc., to produce another 100,000 Oxyview units. The company will produce 30,000 new Oxyview model 203A units for aviation sales and 70,000 Oxyview model 206A. The new model 203A units will provide pilots with valuable and accurate oxygen readings between 0-3 liters/minute. The company is expecting additional orders from their aviation OEM partner, Delta Technology Inc. "There is documented demand for our Oxyview products. We are working with COPD Digest on a full page color advertisement in their next edition as a part of our ad saturation campaign. Tom Pridonoff, President of Accent Plastics and Bill Liang, President of Legend Medical Devices have been extremely helpful in keeping on track with our upcoming new production order. More important is that we have completed our funding program under the Rule 504 Registration," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board. The company filed a Form D registration under Rule-504 on April 6, 2009, and has recently completed the funding program. The company was notified by Worldwide Stock Transfer on Wednesday this week that the 504 registration had reached its limit. There is no longer a 504 registration or issuance of shares under Rule 504 being implemented at this time
IP: Logged |
posted
What the junk is going on?!?! Can anyone explain how a stock goes down 3% after saying "Our orders increase...we will be getting more money"? IGNT makes no sense. It gains when the company says, "We want to sell ourselves...we're just too lazy", but loses value when they get more business????????
IP: Logged |
posted
A lot of us are wondering the same, but we are holding strong! Volume is up, compared to the past few days.
I bet more good news or atleast some news will be posted around 5:30pm E.T. today. Watch and see. It amazes me that they will not post during trading hours.
IP: Logged |
Ingen's New Oxyview-Nasal Cannula Initiates Market Introduction Tomorrow 41 minutes ago - Globenewswire
IGNT 0.0084 6.33%
As of 3:01 PM ET 6/23/09 Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company will begin to introduce the new Oxyview-Nasal Cannula tomorrow. The new Oxyview-Nasal Cannula is a medical device that provides home oxygen patients with a quality soft tip nasal cannula and oxygen flow meter combined. This new device is sold for $5.75 retail, and is price competitive with other nasal cannulas that do not include an oxygen flow meter. The company manufactures Oxyview, an in-line gravity independent oxygen flow meter that provides any patient using oxygen with vital information about the flow rate nearest the patient, as well as provides assurance that the oxygen delivery system is properly functioning. The Oxyview-Nasal Cannula provides the patients and clinicians with several key improvement factors. The Oxyview-Nasal Cannula displays the actual prescribed oxygen flow rate. Without this new device, there is no confirmation of flow rate at the delivery site. As a result, the new Oxyview-Nasal Cannula eliminates unnecessary telephone calls between the patient and the oxygen provider in regards to receiving oxygen or equipment problems. It also provides the oxygen supplier an improved means to trouble shoot equipment problems over the telephone without a required on-site visit. This added assurance to both the patient and oxygen provider improves oxygen therapy and decreases costs that are essentially paid through Medicare, Medicaid and third party insurance carriers. There are a recorded 23 million patients in the U.S. using home oxygen therapy, and all of them, not including hospitalized patients, use several nasal cannulas each month. There are an estimated 600 million patients worldwide that require home oxygen therapy. The nasal cannula (NC) is a device used to deliver supplemental oxygen to a patient or person in need of extra oxygen. This device consists of a plastic tube which fits behind the ears, and a set of two prongs which are placed in the nostrils. Oxygen flows from these prongs. The nasal cannula is connected to an oxygen tank, a portable oxygen generator, or a wall connection in a hospital via a flow meter. The nasal cannula carries 1-6 liters of oxygen per minute. There are also infant or neonatal nasal cannulas which carry less than one liter per minute; these also have smaller prongs. The oxygen fraction provided to the patient ranges roughly from 24% to 35%. The nasal cannula was invented by Wilfred Jones and patented in 1949 by his employer, BOC. The company has been selling Oxyview as an individually packaged respiratory product, and has now developed a disposable and more affordable Oxyview flow meter that will be attached and prepackaged to a variety of nasal cannula products for the 23M home oxygen patients in the USA and 600M patients worldwide. The company will sell the new Oxyview-Cannula under the Ingen logo. The potential market size for the new Oxyview-Cannula is a conservative estimate of $200M per year in the U.S. and $150M per year outside the U.S. "Beginning tomorrow, the company website will include the new Oxyview-Nasal Cannula and deliveries will commence. We have scheduled advertising with COPD Digest and other large respiratory publications," stated Scott Sand, CEO and Chairman of Ingen Technologies. About Oxyview: Oxyview is a proprietary medical device with U.S.-issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the US. COPD is the fifth leading cause of death in the US and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the US, the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview costs less than a single service call.
IP: Logged |
posted
This is starting to make a move. Up 22% on the day. Could be a busy, busy morning tomorrow (imo). It's been in a decline for the last couple of days, so a turn around seems imminent. Anyone still in this one?
IP: Logged |
posted
My alert came at .0084/share, IGNT just closed at .011/share. Keep it on radar tomorrow, this could be a break out (possibly, jmo). Volume in the last minutes of trading was huge. Keep close watch, and do your research. Smash
IP: Logged |
posted
Nice post Proto. That after hours headline seems fantastic. It would have been nice to buy up more shares on that dip, for sure. I think we're setting up for some really nice action for the rest of the week. I can see this being both a long and short play. There's really no telling how high this can move since we're only at .011/share right now. I'm considering buying up some more shares early tomorrow if the market begins to reacts positively to this news. This is definitely one to research and radar. I have a good feeling about this. Good luck proto and others.
IP: Logged |
posted
Came down hard after strong open...seems to be regaining momentum after release of news:
Ingen to launch new Oxyview-Nasal Cannula 3 minutes ago - Datamonitor
IGNT 0.0094 -14.55%
As of 9:53 AM ET 6/24/09 Ingen Technologies, a medical device manufacturer, has reported that it will introduce the new Oxyview-Nasal Cannula. The new Oxyview-Nasal Cannula is a medical device that provides home oxygen patients with a quality soft tip nasal cannula and oxygen flow meter combined. This new device is sold for $5.75 retail, and is reportedly price competitive with other nasal cannulas that do not include an oxygen flow meter. The company has been selling Oxyview as an individually packaged respiratory product, and has now developed a disposable and more affordable Oxyview flow meter that will be attached and prepackaged to a variety of nasal cannula products. The company will sell the new Oxyview-Cannula under the Ingen logo. According to Ingen, the Oxyview-Nasal Cannula displays the actual prescribed oxygen flow rate. Without this new device, there is no confirmation of flow rate at the delivery site. As a result, the new Oxyview-Nasal Cannula eliminates unnecessary telephone calls between the patient and the oxygen provider for receiving oxygen or equipment problems. It also provides the oxygen supplier an improved means to trouble shoot equipment problems over the telephone without a required on-site visit. This added assurance to both the patient and oxygen provider improves oxygen therapy and decreases costs that are essentially paid through Medicare, Medicaid and third party insurance carriers, the company said.
IP: Logged |
Ingen to Hire Investment Banker for Sale of Company Monday 06/29/2009 4:15 PM ET - Globenewswire
As of 3:59 PM ET 6/29/09 Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company would seek an investment bank to handle a sharebuyout or merger.
"The company is looking into hiring an Investment Banker to evaluate potential bids for the sale of Ingen Technologies. We are committed in doing our very best to enhance shareholder value and at the same time increase corporate growth and earnings," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
About Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 Billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
posted
Ingen Receives Positive Market Response and Fulfills On-Line Orders of the New Oxyview Nasal Cannula Jun 30, 2009 2:04:00 PM 2009 GlobeNewswire, Inc.
YUCAIPA, Calif., June 30, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company has started to receive on-line orders of the new Oxyview Nasal Cannula.
The company received many new orders of the 10-Pack and 50-Pack on-line purchases for the new Oxyview Nasal Cannula since its introduction last week. The 50-Pack unit sells for $150.00, and the 10-Pack unit sells for $40.00.
"This is a good sign. Both patients and suppliers are purchasing the new Oxyview Nasal Cannula through our on-line purchasing program available on our website. There were as many single purchases for $5.75 as there were 10- and 50-Pack purchases. This is a very high quality product for the home oxygen patients, and very much needed," stated Christopher Wirth, Chief Operations Officer.
Oxyview is a proprietary medical device with U.S. issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the U.S. and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview cost less than a single service call.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
posted
Ingen to Seek 5 to 7 Cents a Share On Future Buyout Jun 30, 2009 4:15:00 PM 2009 GlobeNewswire, Inc.
YUCAIPA, Calif., June 30, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company would seek a 5 to 7 cents a share on a buyout or merger.
"We have turned this company around and it has been awhile in coming; but we are finally in the home stretch heading towards profitability. With this turnaround Ingen would entertain any bidders between 5 and 7 cents," stated Thomas Neavitt, Chief Financial Officer.
"We are evaluating various investment bankers and have not ruled out a possible acquisition or merger. We are committed in doing our very best to enhance shareholder value and at the same time increase corporate growth and earnings," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
About Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
CONTACT: Ingen Technologies, Inc. Chris Wirth 909-790-7180 info*ingen-tech.com www.INGEN-TECH.COM
-------------------- " Cash is King "
IP: Logged |
posted
News released twice today. Once in the afternoon that sent it to .013, closed at .01. News released after the close could send it on another run tomorrow morning .... imho
-------------------- " Cash is King "
IP: Logged |
posted
This story seems pretty huge right? If the company is looking for a bid between 5 to 7 cents, aren't they insinuating that the stock is worth that much. Obviously these are considered "forward-looking" statements, but nonetheless, good ones. I'm watching this closely tomorrow, could definitely go for a run. But the volume seems to be too high for its own good. Seems like someone is always undercutting the ASK price. We'll see I guess. Always do your own research, Smash
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Confused]](confused.gif)
